الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
This is retrospective study carried out on patients diagnosed and treated as metastatic breast cancer at Clinical Oncology and Nuclear Medicine Department, Menofia University from January 2015 to December 2019.
A total of 265 patients with MBC, were included in this study.
In the current study we found that the number of the sites of metastasis was 429 sites including 182 cases (68.7 %) with bone metastasis, 142 (53.56%) cases with lung metastasis and 105 (39.6 %) cases with liver metastasis.
There was statistically significant improvement of ORR in patients with bone metastasis with luminal subtype received GemCarbo compared to patients received hormonal treatment.
There was statistically significant improvement of CBR in patients with liver metastasis with luminal subtype received Taxane compared to patients received Gem-Carbo. There was statistically significant improvement of ORR in patients received hormonal TTT and Taxane compared to patients received Capecitabine in patients with lung metastasis, luminal subtype. There was statistically significant improvement in ORR in patients received Taxane and Chemotherapy +anti HER2neu compared to patients received Anthracyclin in the presence of lung metastasis in HER2neu over expression subtype. There was statistically significant improvement in ORR in patients received Anthracyclin and Taxane compared with Capecitabine in the presence of liver metastasis in TNBC.
There was statistically significant improvement of ORR in patients received Anthracyclin over patients received Capecitabine in the presence of lung metastasis in TNBC. In the current study, Median overall survival of all cases (n=265) about 27.3 months with 18 % of the cases still alive at 5 year follow up, Median progression free survival of all cases (n=265) about 14 months with 8.4% of the cases show no progression after 5 years. Median progression free survival of all cases with metastatic breast cancer to the bone (n=182) was 17 months .While, median progression free survival of all cases with metastatic breast cancer to the liver (n=105) was 11 months and, median progression free survival of all cases with metastatic breast cancer to the lung (n=142) was 11 months. In the current study, median progression free survival of all cases with luminal MBC (n=200) was 16 months while, median progression free survival of all cases with HER2NEU overexpression MBC (n=48) was 14 months and median progression free survival of all cases with metastatic TNBC (n=17) was 11 months.